Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 2;11(5):1364.
doi: 10.3390/jcm11051364.

Thrombocytopenia and Therapeutic Strategies after Allogeneic Hematopoietic Stem Cell Transplantation

Leyre Bento  1   2 , Mariana Canaro  1   2 , José María Bastida  3 , Antonia Sampol  1   2
Affiliations
Review

Thrombocytopenia and Therapeutic Strategies after Allogeneic Hematopoietic Stem Cell Transplantation

Leyre Bento et al. J Clin Med. .

Abstract

Thrombocytopenia following allogeneic hematopoietic stem cell transplantation is a usual complication and can lead to high morbidity and mortality. New strategies, such as the use of another graft versus host-disease prophylaxis, alternative donors, and management of infections, have improved the survival of these patients. The mechanisms are unknown; therefore, the identification of new strategies to manage this potentially serious problem is needed. Thrombopoietin receptor agonists are currently available to stimulate platelet production. Some small retrospective studies have reported their potential efficacy in an allogeneic stem cell transplant setting, confirming good tolerability. Recent studies with higher numbers of patients also support their safety and efficacy in this setting, hence establishing the use of these drugs as a promising strategy for this post-transplant complication. However, prospective trials are needed to confirm these results.

Keywords: allogeneic stem cell transplantation; morbidity; thrombocytopenia; thrombopoietin receptor agonists.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Kuzmina Z., Eder S., Böhm A., Pernicka E., Vormittag L., Kalhs P., Petkov V., Stary G., Nepp J., Knobler R., et al. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: Results of a prospective study. Leukemia. 2012;26:746–756. doi: 10.1038/leu.2011.257. - DOI - PubMed
    1. Akahoshi Y., Kanda J., Gomyo A., Hayakawa J., Komiya Y., Harada N., Kameda K., Ugai T., Wada H., Ishihara Y., et al. Risk Factors and Impact of Secondary Failure of Platelet Recovery after Allogeneic Stem Cell Transplantation. Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant. 2016;22:1678–1683. doi: 10.1016/j.bbmt.2016.06.003. - DOI - PubMed
    1. Bielski M., Yomtovian R., Lazarus H.M., Rosenthal N. Prolonged isolated thrombocytopenia after hematopoietic stem cell transplantation: Morphologic correlation. Bone Marrow Transplant. 1998;22:1071–1076. doi: 10.1038/sj.bmt.1701499. - DOI - PubMed
    1. First L.R., Smith B.R., Lipton J., Nathan D.G., Parkman R., Rappeport J.M. Isolated thrombocytopenia after allogeneic bone marrow transplantation: Existence of transient and chronic thrombocytopenic syndromes. Blood. 1985;65:368–374. doi: 10.1182/blood.V65.2.368.368. - DOI - PubMed
    1. Bruno B., Gooley T., Sullivan K.M., Davis C., Bensinger W.I., Storb R., Nash R.A. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2001;7:154–162. doi: 10.1053/bbmt.2001.v7.pm11302549. - DOI - PubMed

LinkOut - more resources